Streetbeat News

Stock Prices

CLOV

Clover Health Investments has announced that it is now in compliance with Nasdaq's minimum bid price requirement.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:16 pm

V

Financial giants have shown a bullish interest in Visa (NYSE:V) through unusual options trades. Analysis reveals a mix of bullish and bearish sentiments, with a price target range of $240 to $300. Visa's stock is currently trading at $273.6, with a slight increase of 0.03%. The next earnings report is due in 27 days, and analysts have a consensus target price of $330.

Portfolio Pulse from Benzinga Insights

June 26, 2024 | 8:16 pm

AVAV

AeroVironment (NASDAQ:AVAV) reported Q4 earnings of $0.43 per share, significantly beating the analyst estimate of $0.21. Sales also surpassed expectations, coming in at $196.98 million against the $188.56 million estimate. Despite the earnings beat, this represents a 56.57% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:15 pm

ADUS

Addus HomeCare shares are trading lower following the announcement of a proposed public offering of 1.50 million shares of its common stock.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:15 pm

BA

FXI

Boeing is reportedly resuming widebody aircraft deliveries to China, according to sources cited by Reuters.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:15 pm

BA

Boeing shares are trading higher on reports that the company is resuming widebody deliveries to China.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:14 pm

LEVI

Levi Strauss & Co shares are trading lower after the company reported mixed Q2 financial results and issued FY24 EPS guidance with its midpoint below estimates.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:14 pm

CASI

CASI Pharmaceuticals shares are trading higher following the announcement of a $15 million private placement financing.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:14 pm

FUL

H.B. Fuller has revised its FY24 adjusted EPS outlook from a range of $4.15 - $4.45 to $4.20 - $4.45, with an estimated EPS of $4.30.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:13 pm

CASI

CASI Pharmaceuticals has announced a $15 million private placement financing led by Venrock Healthcare Capital Partners, Foresite Capital, Panacea Venture, and Dr. Wei-Wu He.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 8:12 pm